Brief: Charles Newton Resigns As CFO Of Lyell Immunopharma - SEC Filing
Sept 16 (Reuters) - SEC Filing: LYELL IMMUNOPHARMA INC - CHARLES NEWTON RESIGNS AS CFO OF LYELL IMMUNOPHARMA - SEC FILING Source text: [ID:n0001193125-25-205020] Further company coverage: LYEL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma